Highlights SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
44.84 ^USD	+0.16%		+9.66%	+22.85%

May. 15	Transcript : SpringWorks Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM
May. 02	Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss	May. 02	MT
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, vs. Street Est of $13.1M	May. 02	MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment	Mar. 04	MT
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	Mar. 04	CI
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows	Feb. 27	MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q4 Revenue $5.4M	Feb. 27	MT
Key Jobs Report Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Tuesday	Dec. 05	MT
SpringWorks non-cancerous tumor drug to be priced at $29,000 per month in US	Nov. 28	RE
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO? (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors	Nov. 27	CI
US FDA approves SpringWorks Therapeutics' non-cancerous tumor treatment	Nov. 27	RE
SpringWorks Therapeutics, Inc. Announces Positive Topline Results from the Phase 2B ReNeu Trial of Mirdametinib in NF1-PN	Nov. 16	CI
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
SpringWorks Therapeutics, Inc. Announces PDUFA Date Extension for Nirogacestat NDA	23-06-05	CI
Springworks Therapeutics, Inc. Announces Data from Two Collaboration-Sponsored Clinical Studies Evaluating Nirogacestat in Combination with B-Cell Maturation Agent in Patients with Relapsed or Refractory Multiple Myeloma	23-05-11	CI
SpringWorks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-03	CI
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
SpringWorks Therapeutics Gets FDA Priority Review for Nirogacestat to Treat Desmoid Tumors	23-02-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Highlights

Filters